참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 2-Bromo-4-nitrotoluene | HCID 82189 | — |
| 반응물 | Oxetan-3-amine hydrochloride | HCID 23062080 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 촉매 | (R)-(-)-1-[(S)-2-(Dicyclohexylphosphino)ferrocenyl]ethyldi-t-butylphosphine;Ferrocene, 1-[(1R)-1-[bis(1,1-dimethylethyl)phosphino]ethyl]-2-(dicyclohexylphosphino)-, (2R)- | HCID 144543273 | — |
| 생성물 | N-(2-methyl-5-nitrophenyl)oxetan-3-amine | HCID 80494079 | 28.82% |
반응 단계
2-bromo-1-methyl-4-nitrobenzene (864 mg, 4mmol), oxetan-3-amine hydrochloride (438 mg, 4 mmol), CS2CO3 (3910 mg, 12.00 mmol), palladium(II) acetate (44.9 mg, 0.20 mmol), (R)-(-)-1-[(S)-2-(Dicyclohexylphosphino)ferrocenyl]ethyldi-t- butylphosphine (224 mg, 0.40 mmol) in 1,4-doxane was degased, inflated with Ar and heated at 90 oC for 5h. LCMS showed some product peak. Silica gel 2g was added to the mixture, evaporated all solvents in GeneVac. The sample was dry loaded for purification by ISCO (Hexane/EtOAc=100/10-100/50) N-(2-methyl-5-nitrophenyl)oxetan-3-amine (240 mg, 28.8 %) 1H NMR (400 MHz, CD2Cl2) d: 7.47 (dd, 1H), 7.14 (d, 1H), 6.98 (s, 1H), 4.99 (t, 2H), 4.63 (m, 1H), 4.46 (t, 2H), 4.20(m, 1H), 2.18 (s, 3H). LCMS: 209 [M+H]+.
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-85488250153944e595f74578eeba1555 |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|